Repatha - evolocumab, first in Europe registered inhibitors PCSK

Abstract

Cardiovascular diseases (CVD) are the leading cause of death. Evolocumab is an effective drug in the treatment of hypercholesterolemia and preventive cardiology.

Keywords

• Hyperlipoproteinemia
• statins
• ezetimibe
• familial hypercholesterolemia
• PCSK9 inhibitors
• evolocumab